Wegovy Dose Escalation Schedule: The Official Titration Protocol Explained

The Wegovy escalation schedule

Wegovy (semaglutide) uses a 5-stage dose escalation over 16–20 weeks before reaching the 2.4 mg maintenance dose. The schedule is in the FDA-approved prescribing label:

Each pen contains exactly 4 doses (1 month of treatment). The escalation was designed so patients move to the next pen after completing the previous one.

Why escalation matters

The primary reason for the gradual escalation is tolerability — specifically, GI side effect management. Higher doses of semaglutide produce greater nausea, vomiting, and GI discomfort. The titration schedule allows the body to adjust progressively to GLP-1 receptor activation.

At the 0.25 mg starter dose, most patients notice little effect — both therapeutically (modest appetite reduction) and in terms of side effects. The GI effects become most noticeable at the 0.5 mg and 1 mg doses for most patients, and the jump from 1.7 mg to 2.4 mg is often the most challenging step.

The titration also allows the prescriber to assess tolerability — if side effects are severe at 0.5 mg, the prescriber can extend time at that dose before advancing.

What to expect at each dose stage

0.25 mg (weeks 1–4)

Most patients notice minimal effect. Appetite may be slightly reduced. GI symptoms are uncommon. This is essentially a sub-therapeutic dose designed to initiate receptor adaptation. Weight loss at this stage is typically 0–2 lbs. For a detailed breakdown of what to expect each week on semaglutide, see week-by-week results on GLP-1.

0.5 mg (weeks 5–8)

The first therapeutically meaningful dose. Appetite suppression becomes noticeable. Nausea is most commonly reported at this transition — days 2–4 after the first 0.5 mg injection are typically the worst days. Most patients adapt within 2 weeks.

1 mg (weeks 9–12)

Meaningful therapeutic dose. Significant appetite suppression in most patients. Weight loss typically accelerating. Nausea may recur briefly after each dose escalation, then settle.

1.7 mg (weeks 13–16)

Close to maintenance efficacy. This stage is important for identifying patients who experience unacceptable side effects at higher doses — some patients will ultimately maintain at 1.7 mg rather than escalating to 2.4 mg.

2.4 mg (week 17 onwards)

The approved maintenance dose and the most effective for weight loss outcomes. Side effects are worst in the first 2–4 weeks of maintenance dose, then stabilise for most patients.

What happens if side effects are intolerable at a dose step

The prescribing label allows extended time at any dose step before escalating:

"If patients do not tolerate a dose increase, the previous dose can be used for an additional 4 weeks before attempting to increase the dose again."

This means a slower escalation is legitimate and not a protocol deviation. Many patients benefit from:

• 8 weeks at 0.5 mg (instead of 4) if nausea is significant
• 8 weeks at 1 mg before advancing
• Extended time at 1.7 mg before moving to 2.4 mg

Telehealth prescribers who automatically advance patients on a fixed schedule regardless of side effects are not following best practice. Patients who find side effects difficult should explicitly request a slower titration with their prescriber.

Stopping escalation at a lower maintenance dose

Not all patients need to reach 2.4 mg. The 2.4 mg dose produces the best average weight loss outcomes in trials, but individual patients may find:

• 1 mg or 1.7 mg provides adequate appetite suppression for their goals
• GI side effects at 2.4 mg outweigh the marginal benefit over 1.7 mg

The prescribing label supports stopping escalation at any dose that is tolerable and effective for the patient. There is no clinical requirement to reach 2.4 mg.

Ozempic off-label for weight loss: different doses apply

Ozempic (semaglutide for T2D) is sometimes prescribed off-label for weight loss. The Ozempic titration schedule is different from Wegovy — it escalates to a maximum of 2 mg (not 2.4 mg) and uses a different escalation pace. Patients prescribed Ozempic off-label for obesity should follow the Ozempic titration schedule, not the Wegovy schedule, even though the drug is chemically identical.

Compounded semaglutide: titration challenges

Compounded semaglutide is typically provided as a multi-dose vial with instructions for self-dosing. For correct injection technique, see the semaglutide injection guide. Unlike the branded pen which contains a pre-set dose, the compounded formulation requires the patient to draw the correct volume corresponding to the desired dose.

Compounding pharmacy dosing instructions vary significantly:

• Some use the same 0.25–0.5–1.0–1.7–2.4 mg schedule as Wegovy
• Some use different escalation increments (e.g., 0.25, 0.5, 0.75, 1.0, 1.25 mg in smaller steps)
• Conversion between concentration and volume requires calculation

Patients on compounded semaglutide should follow the dose instructions provided by their specific pharmacy, as formulation concentrations vary (typically 5 mg/mL but some compounders use different concentrations).

Missed injections and dose management

Missed by less than 5 days: Take the dose as soon as possible, then resume the usual day for the following week's dose.

Missed by more than 5 days: Skip the missed dose and resume on the next scheduled injection day. Do not double-dose.

Long gap (more than 4 weeks): Consult your prescriber. Many will recommend returning to a lower dose to re-initiate rather than resuming at the previous maintenance dose.

Summary

The Wegovy dose escalation schedule is a 5-stage, 16–20 week titration from 0.25 mg to 2.4 mg designed to minimise GI side effects. Each stage corresponds to one pen (4 doses). Slower escalation is explicitly allowed in the prescribing label for patients with significant side effects. Not all patients need to reach 2.4 mg — lower maintenance doses are appropriate for patients who achieve adequate benefit with fewer side effects at a lower dose.